<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404195</url>
  </required_header>
  <id_info>
    <org_study_id>HVVV-Log-01</org_study_id>
    <secondary_id>HSJDPAM01SARCOP2011</secondary_id>
    <secondary_id>ViamedValvaSarcoHF</secondary_id>
    <nct_id>NCT01404195</nct_id>
  </id_info>
  <brief_title>Hyperprotein Nutritional Intervention in Elderly Patients With Hip Fracture and Sarcopenia</brief_title>
  <acronym>HIPERPROT</acronym>
  <official_title>High-protein Nutritional Intervention Based on β-hydroxy-β-methylbutirate, Vitamin D3 and Calcium on Obese and Lean Aged Patients With Hip Fractures and Sarcopenia. The HIPERPROT-GER Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Viamed Valvanera, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Viamed Valvanera, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. RATIONALE The unique characteristic of our study lies in the attempt to reverse the
           functional impairment experienced by sarcopenic patients with hip fracture using
           nutritional intervention. What makes this study different from prior studies is that it
           will be conducted in a hospital setting, unlike most prior studies, which were conducted
           in a community setting. The association between muscle mass and strength, inflammatory
           indices, and functional impairment versus dependence and fragility will also be
           measured.

        2. HYPOTHESIS The hypothesis of our study is that nutritional intervention enriched in
           metabolites of essential amino acids (beta-hydroxy-beta-methylbutyrate) is effective for
           treating sarcopenia in elderly patients with hip fracture and improves functional level.

        3. OBJECTIVES Primary objective is to assess functional improvement after nutritional
           intervention in sarcopenic patients with hip fracture, as measured using Barthel index.

           Secondary objectives will include: 1) to show the relationship between metabolic and
           inflammatory indices and sarcopenia; 2) to show how sarcopenia and its treatment
           influence the risk of fall; 3) to show muscle mass improvement; 4) to show increased
           strength; 5) to assess mortality and morbidity.

        4. EXPECTED RESULTS The investigators expect to find that the supplemented group
           experiences throughout the study period a significant improvement in functional status
           (Barthel index), an increase in muscle mass, and a reduction in fat mass. An increased
           strength and a reduction in associated complications (falls) are also expected. The
           investigators hope to be able to show reductions in inflammatory indices and insulin
           resistance.

      To conclude, by improving muscle strength and mass the investigators expect to find a
      reduction in the disability and dependence of this population group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION Sarcopenia is the loss of muscle mass and function associated to age. Rosemberg
      first spoke of sarcopenia in 1989. A progressive loss of muscle mass occurs from
      approximately 40 years of age. This loss is estimated at about 8% by decade until the age of
      70 years, after which the loss increases to 15% by decade. Healthcare costs attributable to
      sarcopenia in the United States (US) in 2000 were estimated to be 18.5 billion dollars.

      It would be natural to assume a direct relationship between muscle mass and strength, but
      loss of muscle mass is not the main mechanism for loss of strength.

      Proximal femur (hip) fracture is a substantial cause of morbidity and mortality in the
      elderly. One-year mortality after a hip fracture ranges from 12% and 37%, with an 11%
      incidence during the first few months.

      Twenty-five percent of elderly patients with hip fracture require institutionalization, at
      least temporary, and only 40% fully recover their pre-fracture functional status.

      Nutritional therapy, particularly beta-hydroxy-beta-methylbutyrate (HMB), a metabolite of the
      essential amino acid, leucine, has aroused great expectations. All prior studies about
      nutritional supplementation with HMB have shown an improved muscle metabolism, decreased
      protein degradation, and a significant increase in fat-free mass in both young and elderly
      people.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Barthel index</measure>
    <time_frame>On admission to hospital and at discharge.</time_frame>
    <description>functional improvement after nutritional intervention in sarcopenic patients with hip fracture, as measured using Barthel index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bioelectrical impedance analysis</measure>
    <time_frame>On admission to hospital and at discharge.</time_frame>
    <description>Show muscle mass improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in strength will be measured in the dominant hand using a portable JAMAR dynamometer</measure>
    <time_frame>On admission to hospital and at discharge.</time_frame>
    <description>Show an increased strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death for any cause</measure>
    <time_frame>During admission</time_frame>
    <description>assess mortality and morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Univariate analysis of the relationship between levels of IL-1, IL-6 and TNF-alpha and values of bioelectrical impedance</measure>
    <time_frame>On admission to hospital and at discharge</time_frame>
    <description>To show the relationship between inflammatory indices and sarcopenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of sarcopenia</measure>
    <time_frame>hospital admission</time_frame>
    <description>To determine the prevalence of sarcopenia in elderly patients hospitalized for hip fracture.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Hip Fracture</condition>
  <arm_group>
    <arm_group_label>Ensure Plus Advance, Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participating patients will be dispensed two bottles daily, one at breakfast and one in the evening, seven days a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>without supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ensure Plus Advance</intervention_name>
    <description>Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week</description>
    <arm_group_label>Ensure Plus Advance, Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 65 years or older

          -  Diagnosis of traumatic hip fracture

          -  Patients admitted for rehabilitation

          -  Patients signing informed consent.

        Exclusion Criteria:

          -  Stage 4 renal failure

          -  Child C stage hepatic insufficiency

          -  Barthel index &lt; 20 in the six months prior to admission

          -  Dysphagia for liquids

          -  Active oncological disease who are receiving treatment

          -  Severe clinical conditions compromising and threatening their lives

          -  Morbid obesity (BMI &gt; 40)

          -  BMI &lt; 21 kg/m2

          -  Albumin levels &lt; 2.1 g/dL

          -  MNA &lt; 11

          -  Charlson index ≥ 6

          -  diabetes mellitus

          -  Patients not doing rehabilitation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincenzo Malafarina, MD Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Los Manzanos, Lardero, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M Angeles Zulet, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Los Manzanos</name>
      <address>
        <city>Logroño</city>
        <state>La Rioja</state>
        <zip>26140</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol (1985). 2000 Jul;89(1):81-8. Erratum in: J Appl Physiol (1985). 2014 May 15;116(10):1342.</citation>
    <PMID>10904038</PMID>
  </reference>
  <reference>
    <citation>Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.</citation>
    <PMID>20392703</PMID>
  </reference>
  <reference>
    <citation>Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997 May;127(5 Suppl):990S-991S. doi: 10.1093/jn/127.5.990S. Review.</citation>
    <PMID>9164280</PMID>
  </reference>
  <reference>
    <citation>Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999 Mar 1;107(2):123-36.</citation>
    <PMID>10220041</PMID>
  </reference>
  <reference>
    <citation>Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002 May;50(5):889-96.</citation>
    <PMID>12028177</PMID>
  </reference>
  <reference>
    <citation>Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA, Visser M, Newman AB. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1059-64.</citation>
    <PMID>17077199</PMID>
  </reference>
  <reference>
    <citation>Roubenoff R. Sarcopenia and its implications for the elderly. Eur J Clin Nutr. 2000 Jun;54 Suppl 3:S40-7. Review.</citation>
    <PMID>11041074</PMID>
  </reference>
  <reference>
    <citation>Evans WJ, Campbell WW. Sarcopenia and age-related changes in body composition and functional capacity. J Nutr. 1993 Feb;123(2 Suppl):465-8. doi: 10.1093/jn/123.suppl_2.465. Review.</citation>
    <PMID>8429405</PMID>
  </reference>
  <reference>
    <citation>Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, Nevitt M, Harris TB. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002 May;57(5):M326-32.</citation>
    <PMID>11983728</PMID>
  </reference>
  <reference>
    <citation>Peake J, Della Gatta P, Cameron-Smith D. Aging and its effects on inflammation in skeletal muscle at rest and following exercise-induced muscle injury. Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1485-95. doi: 10.1152/ajpregu.00467.2009. Epub 2010 Apr 14. Review.</citation>
    <PMID>20393160</PMID>
  </reference>
  <reference>
    <citation>Paddon-Jones D, Sheffield-Moore M, Urban RJ, Sanford AP, Aarsland A, Wolfe RR, Ferrando AA. Essential amino acid and carbohydrate supplementation ameliorates muscle protein loss in humans during 28 days bedrest. J Clin Endocrinol Metab. 2004 Sep;89(9):4351-8.</citation>
    <PMID>15356032</PMID>
  </reference>
  <reference>
    <citation>Paddon-Jones D, Sheffield-Moore M, Aarsland A, Wolfe RR, Ferrando AA. Exogenous amino acids stimulate human muscle anabolism without interfering with the response to mixed meal ingestion. Am J Physiol Endocrinol Metab. 2005 Apr;288(4):E761-7. Epub 2004 Nov 30.</citation>
    <PMID>15572657</PMID>
  </reference>
  <reference>
    <citation>Jensen GL. Inflammation: roles in aging and sarcopenia. JPEN J Parenter Enteral Nutr. 2008 Nov-Dec;32(6):656-9. doi: 10.1177/0148607108324585. Review.</citation>
    <PMID>18974248</PMID>
  </reference>
  <reference>
    <citation>Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD. Cachexia: a new definition. Clin Nutr. 2008 Dec;27(6):793-9. doi: 10.1016/j.clnu.2008.06.013. Epub 2008 Aug 21.</citation>
    <PMID>18718696</PMID>
  </reference>
  <reference>
    <citation>Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998 Apr 15;147(8):755-63. Erratum in: Am J Epidemiol 1999 Jun 15;149(12):1161.</citation>
    <PMID>9554417</PMID>
  </reference>
  <reference>
    <citation>Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol. 2004 Feb 15;159(4):413-21.</citation>
    <PMID>14769646</PMID>
  </reference>
  <reference>
    <citation>Chumlea WC, Guo SS, Vellas B, Guigoz Y. Techniques of assessing muscle mass and function (sarcopenia) for epidemiological studies of the elderly. J Gerontol A Biol Sci Med Sci. 1995 Nov;50 Spec No:45-51. Review.</citation>
    <PMID>7493217</PMID>
  </reference>
  <reference>
    <citation>Paddon-Jones D, Short KR, Campbell WW, Volpi E, Wolfe RR. Role of dietary protein in the sarcopenia of aging. Am J Clin Nutr. 2008 May;87(5):1562S-1566S. Review.</citation>
    <PMID>18469288</PMID>
  </reference>
  <reference>
    <citation>Volkert D, Berner YN, Berry E, Cederholm T, Coti Bertrand P, Milne A, Palmblad J, Schneider S, Sobotka L, Stanga Z; DGEM (German Society for Nutritional Medicine), Lenzen-Grossimlinghaus R, Krys U, Pirlich M, Herbst B, Schütz T, Schröer W, Weinrebe W, Ockenga J, Lochs H; ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: Geriatrics. Clin Nutr. 2006 Apr;25(2):330-60.</citation>
    <PMID>16735082</PMID>
  </reference>
  <reference>
    <citation>Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003288. doi: 10.1002/14651858.CD003288.pub3. Review.</citation>
    <PMID>19370584</PMID>
  </reference>
  <reference>
    <citation>Flakoll P, Sharp R, Baier S, Levenhagen D, Carr C, Nissen S. Effect of beta-hydroxy-beta-methylbutyrate, arginine, and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women. Nutrition. 2004 May;20(5):445-51.</citation>
    <PMID>15105032</PMID>
  </reference>
  <reference>
    <citation>Malafarina V, Uriz-Otano F, Gil-Guerrero L, Iniesta R, Zulet MA, Martinez JA. Study protocol: High-protein nutritional intervention based on β-hydroxy-β-methylbutirate, vitamin D3 and calcium on obese and lean aged patients with hip fractures and sarcopenia. The HIPERPROT-GER study. Maturitas. 2013 Oct;76(2):123-8. doi: 10.1016/j.maturitas.2013.06.016. Epub 2013 Jul 26.</citation>
    <PMID>23891440</PMID>
  </reference>
  <reference>
    <citation>Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L. Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review. J Am Med Dir Assoc. 2013 Jan;14(1):10-7. doi: 10.1016/j.jamda.2012.08.001. Epub 2012 Sep 13. Review.</citation>
    <PMID>22980996</PMID>
  </reference>
  <reference>
    <citation>Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L. Sarcopenia in the elderly: diagnosis, physiopathology and treatment. Maturitas. 2012 Feb;71(2):109-14. doi: 10.1016/j.maturitas.2011.11.012. Epub 2011 Dec 6. Review.</citation>
    <PMID>22153348</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Viamed Valvanera, Spain</investigator_affiliation>
    <investigator_full_name>Vincenzo Malafarina, MD MSc</investigator_full_name>
    <investigator_title>MD MSc</investigator_title>
  </responsible_party>
  <keyword>Nutritional supplement</keyword>
  <keyword>CaHMB</keyword>
  <keyword>Barthel index</keyword>
  <keyword>Frailty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

